BP
Highly rated in
40
conditions
Highly rated in
40
conditions
Check Dr. Brian E. Persing's experience treating your condition:
About Dr. Brian E. Persing

Brian Persing is a Hematologist Oncology specialist and an Oncologist in Mobile, Alabama. Persing has been practicing medicine for over 20 years and is highly rated in 40 conditions, according to our data. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Lymphocytic Lymphoma SLL, and WT1-Related Wilms Tumor Syndromes. He is licensed to treat patients in Mississippi and Alabama. Persing is currently accepting new patients.

His participating in 3 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Brian E. Persing it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Brian E. Persing accepts the following insurance:

  •  Blue Cross Blue Shield
  •  Ambetter
  •  Molina Healthcare
  •  UnitedHealthcare
  •  Magnolia Health

Call to see if your plan is accepted.
Locations
1660 Spring Hill Ave, Mobile, AL 36604
Other Locations
101 Memorial Hospital Drive, Mob Iii Building 3, Mobile, AL 36608
3rd St, Mobile, AL 36608
Background & Education
Graduate Institution
Sanford School Of Medicine Of University Of South Dakota, 2002
Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in MS
Hospital Affiliations
Mobile Infirmary
USA Health University Hospital
USA Childrens & Womens Hospital
Springhill Medical Center
Thomas Hospital
Pascagoula Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


3 Clinical Trials

Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
View 1 Less Clinical Trial -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors